Eric Helmer

884 total citations
18 papers, 497 citations indexed

About

Eric Helmer is a scholar working on Immunology, Pulmonary and Respiratory Medicine and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Eric Helmer has authored 18 papers receiving a total of 497 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Immunology, 4 papers in Pulmonary and Respiratory Medicine and 4 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Eric Helmer's work include Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (4 papers), Pharmacogenetics and Drug Metabolism (3 papers) and Reproductive System and Pregnancy (3 papers). Eric Helmer is often cited by papers focused on Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (4 papers), Pharmacogenetics and Drug Metabolism (3 papers) and Reproductive System and Pregnancy (3 papers). Eric Helmer collaborates with scholars based in Belgium, United Kingdom and United States. Eric Helmer's co-authors include Marie Teil, Anna Moltó, Astrid van Tubergen, Frauke Förger, Xavier Mariette, Laura Shaughnessy, Jeff Simpson, Ann D. Flynn, René-Marc Flipo and Eliza F. Chakravarty and has published in prestigious journals such as Gastroenterology, Cancer Research and Annals of the Rheumatic Diseases.

In The Last Decade

Eric Helmer

18 papers receiving 483 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eric Helmer Belgium 8 301 144 117 97 68 18 497
Miguel Nogueira Portugal 9 212 0.7× 26 0.2× 61 0.5× 109 1.1× 32 0.5× 21 361
Elyssa Ott United States 9 199 0.7× 34 0.2× 54 0.5× 71 0.7× 28 0.4× 14 491
Noemí Eirís Spain 10 313 1.0× 12 0.1× 100 0.9× 162 1.7× 36 0.5× 21 413
Kasper Fjellhaugen Hjuler Denmark 14 386 1.3× 11 0.1× 175 1.5× 206 2.1× 63 0.9× 20 548
Kenneth Washenik United States 5 42 0.1× 21 0.1× 64 0.5× 115 1.2× 132 1.9× 7 409
S.P. Menting Netherlands 9 504 1.7× 12 0.1× 100 0.9× 192 2.0× 57 0.8× 13 585
M. Lamba United States 8 138 0.5× 10 0.1× 100 0.9× 92 0.9× 76 1.1× 17 356
David R. Czuchlewski United States 11 55 0.2× 49 0.3× 88 0.8× 8 0.1× 145 2.1× 26 402
Ekaterini Politi Greece 11 103 0.3× 83 0.6× 142 1.2× 11 0.1× 6 0.1× 29 487
Mindy Chen United States 9 95 0.3× 8 0.1× 129 1.1× 113 1.2× 30 0.4× 18 384

Countries citing papers authored by Eric Helmer

Since Specialization
Citations

This map shows the geographic impact of Eric Helmer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Helmer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Helmer more than expected).

Fields of papers citing papers by Eric Helmer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric Helmer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Helmer. The network helps show where Eric Helmer may publish in the future.

Co-authorship network of co-authors of Eric Helmer

This figure shows the co-authorship network connecting the top 25 collaborators of Eric Helmer. A scholar is included among the top collaborators of Eric Helmer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric Helmer. Eric Helmer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Gualano, Virginie, et al.. (2023). Drug–drug interaction prediction of ziritaxestat using a physiologically based enzyme and transporter pharmacokinetic network interaction model. Clinical and Translational Science. 16(11). 2222–2235. 2 indexed citations
2.
Díaz, Nieves, M. J. Dominguez, Eric Helmer, et al.. (2023). Abstract CT114: Data from first-in-human study of EXS21546, an A2A receptor antagonist, now progressing into phase 1 in RCC/NSCLC. Cancer Research. 83(8_Supplement). CT114–CT114. 1 indexed citations
3.
Strâmbu, Irina, Christian A. Seemayer, Paul A. Ford, et al.. (2022). GLPG1205 for idiopathic pulmonary fibrosis: a phase 2 randomised placebo-controlled trial. European Respiratory Journal. 61(3). 2201794–2201794. 27 indexed citations
4.
Helmer, Eric, et al.. (2022). Ziritaxestat Drug–Drug Interaction with Oral Contraceptives: Role of SULT1E1 Inhibition. Clinical Pharmacology & Therapeutics. 112(4). 901–908. 5 indexed citations
5.
Helmer, Eric, et al.. (2021). Pharmacokinetics and Metabolism of Ziritaxestat (GLPG1690) in Healthy Male Volunteers Following Intravenous and Oral Administration. Clinical Pharmacology in Drug Development. 11(2). 246–256. 9 indexed citations
6.
Desrivot, Julie, et al.. (2021). Effect of GLPG1205, a GPR84 Modulator, on CYP2C9, CYP2C19, and CYP1A2 Enzymes: In Vitro and Phase 1 Studies. Clinical Pharmacology in Drug Development. 10(9). 1007–1017. 7 indexed citations
7.
Desrivot, Julie, Sonia Dupont, Luc Meuleners, et al.. (2021). GLPG1205, a GPR84 Modulator: Safety, Pharmacokinetics, and Pharmacodynamics in Healthy Subjects. Clinical Pharmacology in Drug Development. 10(9). 994–1006. 5 indexed citations
8.
Nicolas, Jean‐Marie, et al.. (2019). Role of P-glycoprotein in the brain disposition of seletalisib: Evaluation of the potential for drug-drug interactions. European Journal of Pharmaceutical Sciences. 142. 105122–105122. 3 indexed citations
9.
Aar, Ellen van der, Julie Desrivot, Sonia Dupont, et al.. (2019). Safety, Pharmacokinetics, and Pharmacodynamics of the Autotaxin Inhibitor GLPG1690 in Healthy Subjects: Phase 1 Randomized Trials. The Journal of Clinical Pharmacology. 59(10). 1366–1378. 34 indexed citations
10.
Mariette, Xavier, Frauke Förger, Bincy Abraham, et al.. (2019). Lack of placental transfer of certolizumab pegol during pregnancy: Results from CRIB, a prospective, postmarketing, multicenter, pharmacokinetic study. European Journal of Obstetrics & Gynecology and Reproductive Biology. 234. e168–e169. 1 indexed citations
11.
Juárez, Maria, Nieves Díaz, Geoffrey I. Johnston, et al.. (2019). AB0458 A PHASE II RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF OF CONCEPT STUDY OF ORAL SELETALISIB IN PATIENTS WITH PRIMARY SJÖGREN'S SYNDROME (PSS). Annals of the Rheumatic Diseases. 78. 1692–1693. 3 indexed citations
12.
Mariette, Xavier, Frauke Förger, Bincy Abraham, et al.. (2017). Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Annals of the Rheumatic Diseases. 77(2). 228–233. 255 indexed citations
13.
Helmer, Eric, Mark Watling, Emma Jones, et al.. (2017). First-in-human studies of seletalisib, an orally bioavailable small-molecule PI3Kδ inhibitor for the treatment of immune and inflammatory diseases. European Journal of Clinical Pharmacology. 73(5). 581–591. 13 indexed citations
14.
Mariette, Xavier, Frauke Förger, Anna Moltó, et al.. (2017). OP0017 Lack of placental transfer of certolizumab pegol during pregnancy: results from crib, a prospective, postmarketing, multicenter, pharmacokinetic study. Annals of the Rheumatic Diseases. 76. 57–58. 8 indexed citations
15.
Mariette, Xavier, Bincy Abraham, Ann D. Flynn, et al.. (2017). Lack of placental transfer of certolizumab pegol during pregnancy: Results from crib, a prospective, postmarketing, multicenter, pharmacokinetic study. Reproductive Toxicology. 72. 42–43. 2 indexed citations
16.
Helmer, Eric, Jean‐Marie Nicolas, Ad F. Roffel, et al.. (2017). A Dual‐Administration Microtracer Technique to Characterize the Absorption, Distribution, Metabolism, and Excretion of [14C]Seletalisib (UCB5857) in Healthy Subjects. The Journal of Clinical Pharmacology. 57(12). 1582–1590. 5 indexed citations
17.
Abraham, Bincy, Xavier Mariette, Ann D. Flynn, et al.. (2017). Lack of Placental Transfer of Certolizumab Pegol During Pregnancy: Results from Crib, a Prospective, Postmarketing, Multicenter, Pharmacokinetic Study. Gastroenterology. 152(5). S1315–S1316. 3 indexed citations
18.
Glatt, Sophie, Eric Helmer, Birgit Haier, et al.. (2016). First‐in‐human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL‐17A and IL‐17F, in mild psoriasis. British Journal of Clinical Pharmacology. 83(5). 991–1001. 114 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Miguel Nogueira Breakdown of academic impact, for papers by Elyssa Ott Breakdown of academic impact, for papers by Noemí Eirís Breakdown of academic impact, for papers by Kasper Fjellhaugen Hjuler Breakdown of academic impact, for papers by Kenneth Washenik Breakdown of academic impact, for papers by S.P. Menting Breakdown of academic impact, for papers by M. Lamba Breakdown of academic impact, for papers by David R. Czuchlewski Breakdown of academic impact, for papers by Ekaterini Politi Breakdown of academic impact, for papers by Mindy Chen
Rankless by CCL
2026